Biomarkers for Pancreatic Cancer: Is it Ready for Primetime?

  • Richard Kim H. Lee Moffitt Cancer Center. Tampa, FL, USA
  • Amit Mahipal H. Lee Moffitt Cancer Center. Tampa, FL, USA
  • Minsig Choi Wayne State University, Karmonos Cancer Center. Detroit, MI, USA
  • Mohammad Wasif Saif Tufts University School of Medicine. Boston, MA, USA
Keywords: Biological Markers, Equilibrative Nucleoside Transporter 1, Osteonectin, Pancreatic Neoplasms

Abstract

No abstract available.

Image: H. Lee Moffitt Cancer Center. Tampa, FL, USA.

Downloads

Download data is not yet available.

Author Biography

Richard Kim, H. Lee Moffitt Cancer Center. Tampa, FL, USA

H. Lee Moffitt Cancer Center Tampa, Fl, USA

References

American Cancer Society. Cancer Facts & Figures 2013. Atlanta, G.A.C.S.

Conroy, T., et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011. 364(19): p. 1817-25.

Daniel D. Von Hoff DD, Thomas J. Ervin TJ, Francis P. Arena FP, E. Gabriela Chiorean EG, Jeffrey R. Infante JR, Malcolm J. Moore MJ, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 30: 2012 (suppl 34; abstr LBA148).

Moore, M.J., et al., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007. 25(15): p. 1960-6.

Philip, P.A., et al., Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol, 2010. 28(22): p. 3605-10.

Kindler, H.L., et al., Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol, 2010. 28(22): p. 3617-22.

Zhang, J., et al., The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev, 2007. 26(1): p. 85-110.

Giovannetti, E., et al., Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res, 2006. 66(7): p. 3928-35.

Farrell, J.J., et al., Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology, 2009. 136(1): p. 187-95.

Kim, R., et al., Prognostic roles of human equilibrative transporter 1 (hENT1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer, 2011. 117(14): p. 3126-34.

P. Neoptolemos, et al., HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5-FU on the ESPAC trials. J Clin Oncol 2013. 31(suppl; abstr 4006).

Elizabeth Poplin, et al., Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment. J Clin Oncol, 2013. 31: p. suppl; abstr 4007.

Funk, S.E. and E.H. Sage, The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci U S A, 1991. 88(7): p. 2648-52.

Infante, J.R., et al., Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. Journal of Clinical Oncology, 2007. 25(3): p. 319-325.

Marianne Sinn, et al., SPARC in pancreatic cancer: Results from the CONKO-001 study. J Clin Oncol 2013. 31: p. (suppl; abstr 4016).

Puolakkainen, P.A., et al., Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res, 2004. 2(4): p. 215-24.

Brekken, R.A., et al., Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest, 2003. 111(4): p. 487-95.

Von Hoff, D.D., et al., Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial. Journal of Clinical Oncology, 2011. 29(34): p. 4548-4554.

Ueno, H., et al., Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol, 2013. 31(13): p. 1640-8.

Ajani, J.A., et al., Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol, 2010. 28(9): p. 1547-53.

Ajani, J.A., et al., Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol, 2005. 23(28): p. 6957-65.

H. Lee Moffitt Cancer Center. Tampa, FL, USA
Published
2013-07-10
How to Cite
Kim, R., Mahipal, A., Choi, M., & Saif, M. (2013). Biomarkers for Pancreatic Cancer: Is it Ready for Primetime?. JOP. Journal of the Pancreas, 14(4), 309-311. https://doi.org/10.6092/1590-8577/1676